[Ip-health] drug naming/patents/exclusivity

[Kirsten Myhr]

-----Opprinnelig melding-----
Fra: Kirsten Myhr [mailto:kirsten.myhr@relis.ulleval.no]
Sendt: 23. mai 2007 07:08
Til: Sue Rochman
Emne: SV: [Ip-health] drug naming/patents/exclusivity


Another example

Lilly sells duloxetine as Cymbalta for depression and Yentreve for
incontinence. Interesting that EU was quick to approve Yentreve on very weak
evidence but Lilly actually withdrew their US application because they
understood that FDA would not approve it....

There are probably several reasons for this trend. I worry that by giving
psychotropic drugs different brand names, doctors forget that they are
actually prescribing 'strong medicines' for non-psychiatric disorders.

This reference was sent from a colleague directly to Sue Rochman:

http://www.pjonline.com/pdf/spectrum/pj_20070203_dualbranding.pdf


Kirsten Myhr, MScPharm, MPH
Ulleval University Hospital
Norway

-----Opprinnelig melding-----
Fra: ip-health-admin@lists.essential.org
[mailto:ip-health-admin@lists.essential.org]Pa vegne av Sue Rochman
Sendt: 19. mai 2007 17:17
Til: ip-health@lists.essential.org
Emne: [Ip-health] drug naming/patents/exclusivity

Also, can anyone explain, or recommend someone who can comment on, the
benefits that pharmaceutical companies get (patent or exclusivity
extensions or otherwise) when they remarket a drug with a new name or
for a new use?

Thanks,
Sue Rochman
Freelance Medical/Health Writer
sue.rochman@earthlink.net